Suggested Topics within your search.
      
      Suggested Topics within your search.
      
    
                      
  
      
    - 
            1221
 - 
            1222
Can nebulised heparin reduce acute lung injury in patients with SARS‑CoV‑2 requiring advanced respiratory support in Ireland: the CHARTER‑Ireland phase Ib/IIa, randomised, parallel-group, open-label study
Published 2025-02-01“…Methods This was a phase Ib/IIa open-label multi-centre, randomised controlled trial. …”
Get full text
Article - 
            1223
Efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB non-small cell lung cancer (periSCOPE): an open-label, single-arm, phase II trialResearch in context
Published 2025-01-01“…Methods: Patients diagnosed with stage IIIB NSCLC through invasive staging approaches and/or PET/CT scans and evaluated as having a high probability of radical resection of the primary lesion and metastatic lymph nodes with clear pathological margins by a multidisciplinary team were enrolled in this open-label, single-arm, phase II trial at a single centre in China. …”
Get full text
Article - 
            1224
Assessing the safety and feasibility of neoadjuvant hormone and radiation therapy followed by robot-assisted radical prostatectomy for treating locally advanced prostate cancer: protocol for an open-label, dose-escalation, single-centre, phase I clinical trial
Published 2020-11-01“…We have designed this trial to investigate whether this combination, which theoretically maximises local control, is a safe and feasible approach for treating locally advanced prostate cancer.Methods and analysis This study is a phase I, open-label study to investigate the safety and feasibility of neoadjuvant hormone and radiation therapy followed by robot-assisted radical prostatectomy by a traditional 3+3 dose-escalation design with four planned radiation dose levels (39.6 Gy/22F, 45 Gy/25F, 50.4 Gy/28F and 54 Gy/30F). …”
Get full text
Article - 
            1225
Multimodal Imaging of Integrin Receptor-Positive Tumors by Bioluminescence, Fluorescence, Gamma Scintigraphy, and Single-Photon Emission Computed Tomography Using a Cyclic RGD Peptide Labeled with a Near-Infrared Fluorescent Dye and a Radionuclide
Published 2009-03-01“…The in vivo distribution of 111 In-labeled LS308 in a 4t1 luc tumor-bearing mouse model was studied by fluorescence, bioluminescence, planar gamma, and single-photon emission computed tomography (SPECT). …”
Get full text
Article - 
            1226
Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [Tc] (AH-113018) or CY 5** (AH-112543) Labeled Peptide
Published 2015-09-01“…A peptide targeting Met labeled with [ 99m Tc] had high affinity in vitro (K d = 3.3 nM) and detected relative changes in Met in human cancer cell lines. …”
Get full text
Article - 
            1227
 - 
            1228
 - 
            1229
 - 
            1230
Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk
Published 2021-06-01“…Introduction There is an urgent need to idenfy treatments for COVID-19 that reduce illness duration and hospital admission in those at higher risk of a longer illness course and complications.Methods and analysis The Platform Randomised trial of INterventions against COVID-19 In older peoPLE trial is an open-label, multiarm, prospective, adaptive platform, randomised clinical trial to evaluate potential treatments for COVID-19 in the community. …”
Get full text
Article - 
            1231
 - 
            1232
Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study
Published 2020-10-01“…Here, we report the results of a phase 2 clinical trial of adoptive cell therapy using zoledronate-expanded autologous Vγ9Vδ2 T-cells for treatment-refractory NSCLC.Methods NSCLC patients who had undergone at least two regimens of standard chemotherapy for unresectable disease or had had at least one treatment including chemotherapy or radiation for recurrent disease after surgery were enrolled in this open-label, single-arm, multicenter, phase 2 study. After preliminary testing of Vγ9Vδ2 T-cell proliferation, autologous peripheral blood mononuclear cells were cultured with zoledronate and IL-2 to expand the Vγ9Vδ2 T-cells. …”
Get full text
Article - 
            1233
 - 
            1234
 - 
            1235
Free Electron Density Gradients Enhanced Biosensor for Ultrasensitive and Accurate Affinity Assessment of the Immunotherapy Drugs
Published 2024-12-01Subjects: Get full text
Article - 
            1236
Dobutamine-induced alterations in internal carotid artery blood flow and cerebral blood flow in healthy adults
Published 2025-02-01Subjects: Get full text
Article - 
            1237
CSTN: A cross-region crop mapping method integrating self-training and contrastive domain adaptation
Published 2025-02-01Subjects: Get full text
Article - 
            1238
Effect of <i>Opuntia ficus-indica</i> Extract in Pro-Healthy Chicken Patties: Physicochemical Properties and Oxidative Stability
Published 2024-12-01Subjects: Get full text
Article - 
            1239
Authenticity Verification of Commercial Poppy Seed Oil Using FT-IR Spectroscopy and Multivariate Classification
Published 2024-12-01Subjects: Get full text
Article - 
            1240
Transient Slope: A Metric for Assessing Heterogeneity from the Dielectrophoresis Spectrum
Published 2024-12-01Subjects: Get full text
Article